Vicore Pharma Holding AB (publ) (FRA:6Y4)

Market Cap	327.29M
Revenue (ttm)	768.92K
Net Income (ttm)	-38.39M
Shares Out	n/a
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.116
Previous Close	1.082
Day's Range	1.116 - 1.116
52-Week Range	0.521 - 1.182
Beta	n/a
RSI	66.68
Earnings Date	Feb 27, 2026

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 29
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6Y4

Financial Performance

Financial numbers in SEK